Glycine

Glycine

SCHEMBL4955985

NC1CCCCN1C(=O)O.NCC(=O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.39
DPP8 Q6V1X1 2/20 0.39
PREP P48147 1/20 0.39
FAP Q12884 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 4/20 0.38
GLRA1 P23415 1/20 0.37
SLC6A9 P48067 1/20 0.37
OR51E2 Q9H255 1/20 0.37
CHRM2 P08172 8/20 0.34
CHRM4 P08173 8/20 0.34
CHRM5 P08912 8/20 0.34
CHRM1 P11229 8/20 0.34
CHRM3 P20309 8/20 0.34
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179330 0.90 GAA (0.36) DPP4DPP8DPP9DPP7CHRM2
SCHEMBL385022 0.90 GAA (0.36) DPP4DPP8DPP9DPP7CHRM2
SCHEMBL30443171 0.88 CHRM2 (0.37) DPP4DPP8FAPDPP9DPP7
SCHEMBL21773024 0.84
SCHEMBL3488662 0.84
SCHEMBL19408961 0.84
Alanine SCHEMBL4955495 0.79 DPP4 (0.44) DPP4DPP8PREPFAPDPP9
Serine SCHEMBL4955395 0.78 DPP7 (0.40) DPP4DPP8FAPDPP9DPP7
SCHEMBL21296547 0.75
SCHEMBL13057112 0.75 DPP4 (0.59) DPP4DPP8PREPFAPDPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439226-B2 Serine protease inhibitors THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2008-10-21 US disclosed
WO-2006043933-A1 SERINE PROTEASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-04-27 WO disclosed
US-20050130883-A1 Serine protease inhibitors THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130883-A1 Serine protease inhibitors PRSS1, TASP1, METAP1 DPP4 248/4885DPP8 185/4885PREP 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.